Original articles
Min-Xia Su, Yu-Lian Xu, Xiao-Ming Jiang, Mu-Yang Huang, Le-Le Zhang, Luo-Wei Yuan, Xiao-Huang Xu, Qi Zhu, Jian-Li Gao, Jia-Hong Lu, Xiuping Chen, Ming-Qing Huang, Yitao Wang, Jin-Jian Lu. c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2[J]. Acta Pharmaceutica Sinica B, 2022, 12(3): 1240-1253

c-MYC-mediated TRIB3/P62+ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2
Min-Xia Sua, Yu-Lian Xua, Xiao-Ming Jianga, Mu-Yang Huanga, Le-Le Zhanga, Luo-Wei Yuana, Xiao-Huang Xua, Qi Zhua, Jian-Li Gaob, Jia-Hong Lua, Xiuping Chena, Ming-Qing Huangc, Yitao Wanga, Jin-Jian Lua,d
a. State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao 999078, China;
b. School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310000, China;
c. College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350000, China;
d. MoE Frontiers Science Center for Precision Oncology, University of Macau, Macao 999078, China
Abstract:
The mammalian target of rapamycin (mTOR) pathway is abnormally activated in lung cancer. However, the anti-lung cancer effect of mTOR inhibitors as monotherapy is modest. Here, we identified that ginsenoside Rh2, an active component of Panax ginseng C. A. Mey., enhanced the anti-cancer effect of the mTOR inhibitor everolimus both in vitro and in vivo. Moreover, ginsenoside Rh2 alleviated the hepatic fat accumulation caused by everolimus in xenograft nude mice models. The combination of everolimus and ginsenoside Rh2 (labeled Eve-Rh2) induced caspase-independent cell death and cytoplasmic vacuolation in lung cancer cells, indicating that Eve-Rh2 prevented tumor progression by triggering paraptosis. Eve-Rh2 up-regulated the expression of c-MYC in cancer cells as well as tumor tissues. The increased c-MYC mediated the accumulation of tribbles homolog 3 (TRIB3)/P62+ aggresomes and consequently triggered paraptosis, bypassing the classical c-MYC/MAX pathway. Our study offers a potential effective and safe strategy for the treatment of lung cancer. Moreover, we have identified a new mechanism of TRIB3/P62+ aggresomes-triggered paraptosis and revealed a unique function of c-MYC.
Key words:    Everolimus    Ginsenoside Rh2    Paraptosis    Aggresomes    P62    TRIB3    c-MYC    Lung cancer   
Received: 2021-06-17     Revised: 2021-08-30
DOI: 10.1016/j.apsb.2021.09.014
Funds: We would like to appreciate Prof. Hua Li and Ms. Jing Guo (Huazhong University of Science and Technology, China), Prof. Su-Hong Chen and Dr. Bo Li (Zhejiang University of Technology, China) for their assistance in animal experiments, Prof. Cheng-Wei He (University of Macau, China) for sponsoring the P62 antibody, Prof. Jian-Bo Wan (University of Macau, China) for suggestions relating to hepatic fat accumulation, Ms. Xin-Ling He, Mr. Zi-Han Ye and Mr. Wei-Bang Yu (University of Macau, China) for their kind help in animal experiments, and Ms. Hai-Lu Su (China Academy of Art, China) for her assistance in drawing Fig. 7J. In addition, we thank the members of the SPF animal facility of Faculty of Health Sciences at the University of Macau for experimental and technical supports. This study was supported by the National Natural Science Foundation of China (No. 81973516) and partially supported by the Science and Technology Development Fund, Macao S.A.R, China (Nos. 024/2016/A1 and 0129/2019/A3), as well as University of Macau (No. CPG2021-00022-ICMS).
Corresponding author: Jin-Jian Lu,E-mai:jinjianlu@um.edu.mo     Email:jinjianlu@um.edu.mo
Author description:
Service
PDF(KB) Free
Print
0
Authors
Min-Xia Su
Yu-Lian Xu
Xiao-Ming Jiang
Mu-Yang Huang
Le-Le Zhang
Luo-Wei Yuan
Xiao-Huang Xu
Qi Zhu
Jian-Li Gao
Jia-Hong Lu
Xiuping Chen
Ming-Qing Huang
Yitao Wang
Jin-Jian Lu

References:
[1] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell 2017; 168: 960-976
[2] Feng FF, Cheng P, Sun C, Wang H, Wang W. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition. Chin J Nat Med 2019; 17: 768-777
[3] Swanton C, Govindan R. Clinical implications of genomic discoveries in lung cancer. N Engl J Med 2016; 374: 1864-1873
[4] Conciatori F, Ciuffreda L, Bazzichetto C, Falcone I, Pilotto S, Bria E, et al. mTOR cross-talk in cancer and potential for combination therapy. Cancers (Basel) 2018; 10: 23
[5] Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, et al. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 2015; 10: 387-391
[6] Wang CZ, Anderson S, Du W, He TC, Yuan CS. Red ginseng and cancer treatment. Chin J Nat Med 2016; 14: 7-16
[7] Wong AS, Che CM, Leung KW. Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview. Nat Prod Rep 2015; 32: 256-272
[8] Li X, Chu S, Lin M, Gao Y, Liu Y, Yang S, et al. Anticancer property of ginsenoside Rh2 from ginseng. Eur J Med Chem 2020; 203: 112627
[9] Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, et al. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer. J Exp Clin Cancer Res 2019; 38: 129
[10] Pak JN, Jung JH, Park JE, Hwang J, Lee HJ, Shim BS, et al. p53 dependent LGR5 inhibition and caspase 3 activation are critically involved in apoptotic effect of compound K and its combination therapy potential in HCT116 cells. Phytother Res 2020; 34: 2745-2755
[11] Liu GW, Liu YH, Jiang GS, Ren WD. The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. Hum Cell 2018; 31: 189-198
[12] Lee H, Lee S, Jeong D, Kim SJ. Ginsenoside Rh2 epigenetically regulates cell-mediated immune pathway to inhibit proliferation of MCF-7 breast cancer cells. J Ginseng Res 2018; 42: 455-462
[13] Wang M, Yan SJ, Zhang HT, Li N, Liu T, Zhang YL, et al. Ginsenoside Rh2 enhances the antitumor immunological response of a melanoma mice model. Oncol Lett 2017; 13: 681-685
[14] Petrillo S, Chiabrando D, Genova T, Fiorito V, Ingoglia G, Vinchi F, et al. Heme accumulation in endothelial cells impairs angiogenesis by triggering paraptosis. Cell Death Differ 2018; 25: 573-588
[15] Sperandio S, Poksay K, de Belle I, Lafuente MJ, Liu B, Nasir J, et al. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix. Cell Death Differ 2004; 11: 1066-1075
[16] Lee D, Kim IY, Saha S, Choi KS. Paraptosis in the anti-cancer arsenal of natural products. Pharmacol Ther 2016; 162: 120-133
[17] Chen X, Chen X, Zhang X, Wang L, Cao P, Rajamanickam V, et al. Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells. Redox Biol 2019; 21: 101061
[18] Kim IY, Shim MJ, Lee DM, Lee AR, Kim MA, Yoon MJ, et al. Loperamide overcomes the resistance of colon cancer cells to bortezomib by inducing CHOP-mediated paraptosis-like cell death. Biochem Pharmacol 2019; 162: 41-54
[19] Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, et al. The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling. Immunity 2020; 52: 668-682.e7
[20] Hetz C, Zhang K, Kaufman RJ. Mechanisms, regulation and functions of the unfolded protein response. Nat Rev Mol Cell Biol 2020; 21: 421-438
[21] Roy A, Kumar A. ER stress and unfolded protein response in cancer cachexia. Cancers (Basel) 2019; 11: 1929
[22] Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, et al. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacol Sin 2021; 42: 451-459
[23] Nogova L, Mattonet C, Scheffler M, Taubert M, Gardizi M, Sos ML, et al. Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: a phase I trial with early pharmacodynamic FDG-PET assessment. Cancer Med 2020; 9: 4991-5007
[24] Jin ZH, Qiu W, Liu H, Jiang XH, Wang L. Enhancement of oral bioavailability and immune response of ginsenoside Rh2 by co-administration with piperine. Chin J Nat Med 2018; 16: 143-149
[25] Chen YC, Huang MY, Zhang LL, Feng ZL, Jiang XM, Yuan LW, et al. Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells. Chin J Nat Med 2020; 18: 517-525
[26] Ruzzolini J, Peppicelli S, Andreucci E, Bianchini F, Margheri F, Laurenzana A, et al. Everolimus selectively targets vemurafenib resistant BRAF(V600E) melanoma cells adapted to low pH. Cancer Lett 2017; 408: 43-54
[27] Schieren G, Bolke E, Scherer A, Raffel A, Gerber PA, Kropil P, et al. Severe everolimus-induced steatohepatis: a case report. Eur J Med Res 2013; 18: 22
[28] Kim SJ, Kang HJ, Kim JS, Eom HS, Huh J, Ko YH, et al. A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. Invest New Drugs 2013; 31: 1514-1521
[29] Nieto N, Rojkind M. Repeated whiskey binges promote liver injury in rats fed a choline-deficient diet. J Hepatol 2007; 46: 330-339
[30] Caldwell S, Ikura Y, Dias D, Isomoto K, Yabu A, Moskaluk C, et al. Hepatocellular ballooning in NASH. J Hepatol 2010; 53: 719-723
[31] Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998; 50: 107-141
[32] Seo MJ, Lee DM, Kim IY, Lee D, Choi MK, Lee JY, et al. Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis. Cell Death Dis 2019; 10: 187
[33] Yoon MJ, Kim EH, Lim JH, Kwon TK, Choi KS. Superoxide anion and proteasomal dysfunction contribute to curcumin-induced paraptosis of malignant breast cancer cells. Free Radic Biol Med 2010; 48: 713-726
[34] Li B, Zhao J, Wang CZ, Searle J, He TC, Yuan CS, et al. Ginsenoside Rh2 induces apoptosis and paraptosis-like cell death in colorectal cancer cells through activation of p53. Cancer Lett 2011; 301: 185-192
[35] Baraz R, Cisterne A, Saunders PO, Hewson J, Thien M, Weiss J, et al. mTOR inhibition by everolimus in childhood acute lymphoblastic leukemia induces caspase-independent cell death. PLoS One 2014; 9: e102494
[36] Addi C, Presle A, Fremont S, Cuvelier F, Rocancourt M, Milin F, et al. The Flemmingsome reveals an ESCRT-to-membrane coupling via ALIX/syntenin/syndecan-4 required for completion of cytokinesis. Nat Commun 2020; 11: 1941
[37] Lee JA, Beigneux A, Ahmad ST, Young SG, Gao FB. ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration. Curr Biol 2007; 17: 1561-1567
[38] Loi M, Molinari M. Mechanistic insights in recov-ER-phagy: micro-ER-phagy to recover from stress. Autophagy 2020; 16: 385-386
[39] Wan Y, Yang Z, Guo J, Zhang Q, Zeng L, Song W, et al. Misfolded Gβ is recruited to cytoplasmic dynein by Nudel for efficient clearance. Cell Res 2012; 22: 1140-1154
[40] Verwilst P, Kim K, Sunwoo K, Kim HR, Kang C, Kim JS. Revealing protein aggregates under thapsigargin-induced ER stress using an ER-targeted thioflavin. ACS Sens 2019; 4: 2858-2863
[41] Cui Y, Parashar S, Zahoor M, Needham PG, Mari M, Zhu M, et al. A COPII subunit acts with an autophagy receptor to target endoplasmic reticulum for degradation. Science 2019; 365: 53-60
[42] Chen Y, Li Q, Li Q, Xing S, Liu Y, Liu Y, et al. p62/SQSTM1, a central but unexploited target: advances in its physiological/pathogenic functions and small molecular modulators. J Med Chem 2020; 63: 10135-10157
[43] Rogov V, Dotsch V, Johansen T, Kirkin V. Interactions between autophagy receptors and ubiquitin-like proteins form the molecular basis for selective autophagy. Mol Cell 2014; 53: 167-178
[44] Hua F, Li K, Yu JJ, Hu ZW. The TRIB3-SQSTM1 interaction mediates metabolic stress-promoted tumorigenesis and progression via suppressing autophagic and proteasomal degradation. Autophagy 2015; 11: 1929-1931
[45] Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776
[46] Caforio M, Sorino C, Iacovelli S, Fanciulli M, Locatelli F, Folgiero V. Recent advances in searching c-Myc transcriptional cofactors during tumorigenesis. J Exp Clin Cancer Res 2018; 37: 239
[47] Crees ZD, Shearrow C, Lin L, Girard J, Arasi K, Bhoraskar A, et al. EGFR/c-Met and mTOR signaling are predictors of survival in non-small cell lung cancer. Ther Adv Med Oncol 2020; 12: 1758835920953731
[48] Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13: 3109-3114
[49] Liang SQ, Buhrer ED, Berezowska S, Marti TM, Xu D, Froment L, et al. mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer. Oncogene 2019; 38: 622-636
[50] Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol 2017; 13: 297-310
[51] Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, Deshaies Y, et al. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 2010; 59: 1338-1348
[52] Li C, Jones PM, Persaud SJ. Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 2011; 129: 307-320
[53] Gomes P, Fleming Outeiro T, Cavadas C. Emerging role of sirtuin 2 in the regulation of mammalian metabolism. Trends Pharmacol Sci 2015; 36: 756-768
[54] Chang GR, Hou PH, Wang CM, Wu CF, Su HK, Liao HJ, et al. Chronic everolimus treatment of high-fat diet mice leads to a reduction in obesity but impaired glucose tolerance. Pharmacol Res Perspect 2021; 9: e00732
[55] Lai DM, Tu YK, Liu IM, Chen PF, Cheng JT. Mediation of beta-endorphin by ginsenoside Rh2 to lower plasma glucose in streptozotocin-induced diabetic rats. Planta Med 2006; 72: 9-13
[56] Lee WK, Kao ST, Liu IM, Cheng JT. Increase of insulin secretion by ginsenoside Rh2 to lower plasma glucose in Wistar rats. Clin Exp Pharmacol Physiol 2006; 33: 27-32
[57] Kress TR, Sabo A, Amati B. MYC: connecting selective transcriptional control to global RNA production. Nat Rev Cancer 2015; 15: 593-607
[58] Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci U S A 2000; 97: 14376-14381
[59] Yoon MJ, Kang YJ, Lee JA, Kim IY, Kim MA, Lee YS, et al. Stronger proteasomal inhibition and higher CHOP induction are responsible for more effective induction of paraptosis by dimethoxycurcumin than curcumin. Cell Death Dis 2014; 5: e1112
[60] Yoon MJ, Kim EH, Kwon TK, Park SA, Choi KS. Simultaneous mitochondrial Ca2+ overload and proteasomal inhibition are responsible for the induction of paraptosis in malignant breast cancer cells. Cancer Lett 2012; 324: 197-209
[61] Nedungadi D, Binoy A, Pandurangan N, Pal S, Nair BG, Mishra N. 6-Shogaol induces caspase-independent paraptosis in cancer cells via proteasomal inhibition. Exp Cell Res 2018; 364: 243-251
[62] Hammoudeh DI, Follis AV, Prochownik EV, Metallo SJ. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc 2009; 131: 7390-7401
[63] Cigliano A, Pilo MG, Li L, Latte G, Szydlowska M, Simile MM, et al. Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget 2017; 8: 90638-90650
[64] Hensen SM, Heldens L, van Enckevort CM, van Genesen ST, Pruijn GJ, Lubsen NH. Heat shock factor 1 is inactivated by amino acid deprivation. Cell Stress Chaperones 2012; 17: 743-755
Similar articles: